Administration of dopaminergic medication in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of PD and patients with PD decreased GPi and increased GPe neuronal activity are consistent with the prediction of the model [14, 15]. This evidence concerns the gene GPI and Parkinson disease.